Result of Annual General Meeting

May 4, 2023

4 May 2023

LungLife AI, Inc.
(the “Company” or “LungLife”)

Result of Annual General Meeting

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at its Annual General Meeting, held at earlier today, all 10 resolutions put to members were passed on a poll.

The number of votes lodged by proxy for and against each of the resolutions proposed, and the number of votes withheld was as follows:

 

 Resolution Votes for % Votes against % Votes withheld
Resolution 1 (Common)

TO receive the Annual Report and Accounts of the Company for the year ended 31 December 2022 together with the directors’ and auditor’s reports thereon.

13,016,289 100.00 0 0.00 0
Resolution 2 (Common)

TO approve the Directors’ Remuneration Policy.

9,997,926 76.81 3,018,363 23.19 0
Resolution 3 (Common)

TO receive the Directors’ Remuneration Report for the year ended 31 December 2022.

13,016,289 100.00 0 0.00 0
Resolution 4 (Common)

THAT Roy Davis be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.

13,016,289 100.00 0 0.00 0
Resolution 5 (Common)

THAT Paul Pagano be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.

13,016,289 100.00 0 0.00 0
Resolution 6 (Common)

THAT David Anderson be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.

 

13,016,289

 

100.00 0 0.00 0
Resolution 7 (Common)

THAT Andrew Boteler be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.

 

13,016,289

 

100.00 0 0.00 0
Resolution 8 (Common)

THAT Sara Barrington be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.

 

13,016,289

 

100.00 0 0.00 0
Resolution 9 (Common)

THAT James McCullough be, and hereby is, re-elected as a director of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.

13,016,289 100.00 0 0.00 0
Resolution 10 (Common)

THAT Crowe UK LLP be, and hereby is, reappointed as auditor of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.

13,016,289 100.00 0 0.00 0

 

The Company notes that, whilst Resolution 2 was passed with the required majority, there was a sizable vote against it representing 23% of shareholders who voted. The Company acknowledges these votes and will engage with shareholders to understand further the reasons behind this vote. The Board will provide an update on this engagement and any actions taken will be published within six months of the AGM.

As at 4 May 2023, there were 25,485,982 common shares in issue. Stockholders are entitled to one vote per common share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.

 

Click HERE for the full announcement.

Recent News

Clinical validation study update
Director share purchases
Half-year Report

Subscribe for Email Alerts

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
chevron-down